Catherine Stehman-Breen

Mimecast Outlook Microsoft Office 365 Google Cloud Hosting Google Tag Manager YouTube Mobile Friendly Nginx Greenhouse.io Bootstrap Framework Vimeo Typekit WordPress.org Remote

cardiovascular disease heart failure gene therapy cardiomyopathies in vivo cellular reprogramming ipsccardiomyoctyes precision medicine cellular regeneration biotechnology: biological products (no diagnostic substances) health care biotechnology research cardiomyopathy heart disease aav vectors biotechnology clinical trials mybpc3 mutation pkp2 mutation gmp manufacturing therapeutic development regenerative medicine patient advocacy disease modeling in vivo models high-throughput screening capsid engineering drug delivery clinical efficacy cgmp drug product biopharmaceutical therapeutic payloads genetic diseases arrhythmogenic right ventricular cardiomyopathy hypertrophic cardiomyopathy fibrosis cardiac function novel therapies orphan drug designation human genetics drug discovery biomarkers genetic therapies small molecule inhibitors hdac6 inhibition dilated cardiomyopathy sarcoplasmic reticulum cardiac reprogramming clinical development therapeutic candidates regulatory pathways patient-centered care disease modification genetic testing diagnostic precision patient journeys collaborations biopharmaceutical leadership innovative therapies clinical-stage therapeutic platforms disease-modifying therapies myocardial infarction small molecule therapeutics patient populations healthcare providers advanced treatment options genetic disorders cardiovascular conditions research collaborations transformative treatments unmet medical needs healthcare sector biotechnology industry gene editing patient outcomes cardiovascular health clinical research participation advanced solutions healthcare institutions genetic medicine curative therapies health wellness & fitness hospital & health care